Company Overview and News

 
FXBY / Foxby Corp. null

2018-10-03 sec.gov
ICI MUTUAL INSURANCE COMPANY, a Risk Retention Group
FXBY

 
Dividend and Income Fund Declares Quarterly Distribution

2018-09-04 accesswire
Notification of Sources of Distribution, Statement Pursuant to Section 19(a) of the Investment Company Act of 1940
FXBY DNI

 
FXBY / Foxby Corp. null

2018-08-28 sec.gov
FOR VALIDATION PURPOSES ONLY - [338293.FOXBY]
FXBY

 
FXBY / Foxby Corp. null

2018-08-28 sec.gov
PAGE 1 000 A000000 06/30/2018 000 C000000 0001068897 000 D000000 N 000 E000000 NF 000 F000000 Y 000 G000000 N 000 H000000 N 000 I000000 6.1 000 J000000 A 001 A000000 FOXBY CORP. 001 B000000 811-09261 001 C000000 2127850900 002 A000000 11 HANOVER SQUARE 002 B000000 NEW YORK 002 C000000 NY 002 D010000 10005 003 000000 N 004 000000 N 005 000000 N 006 000000 N 007 A000000 N 007 B000000 0 007 C010100 1 007 C010200 2 007 C010300 3 007 C010400 4 007 C010500 5 007 C010600 6 007 C010700 7 007 C010800 8 007 C010900 9 007 C011000 10 008 A000001 MIDAS MANAGEMENT CORPORATION 008 B000001 A 008 C000001 801-49079 008 D010001 NEW YORK 008 D020001 NY 008 D030001 10005 012 A000001 SECURITIES TRANSFER CORPORATION 012 B000001 84-0156
FXBY

 
FXBY / Foxby Corp. N-PX

2018-08-02 sec.gov
FXBY

 
Dividend and Income Fund Declares Quarterly Distribution

2018-06-01 accesswire
Notification of Sources of Distribution, Statement Pursuant to Section 19(a) of the Investment Company Act of 1940
FXBY DNI

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 351645106